A role for P2X7 in regulating AML response to chemotherapeutics classically administered in AML, such as daunorubicin and cytarabine, was also suggested by different groups (Lecciso et al., 2017; Salvestrini et al., 2017; Feng et al., 2020; Pegoraro et al., 2020). Here, P2RX7 is linked to acute myeloid leukemia.